<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067858</url>
  </required_header>
  <id_info>
    <org_study_id>10-003</org_study_id>
    <nct_id>NCT02067858</nct_id>
  </id_info>
  <brief_title>An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System</brief_title>
  <official_title>An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven Burton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this clinical research are to evaluate the outcomes and tumor response for early
      stage non-small lung cancer (NSCLC) patients undergoing Stereotactic Body Radiation Therapy
      (SBRT) using four dimensional (4D) Positron Emission Tomography (PET) and Computed Tomography
      (CT), Cone-Beam Computed Tomography (CBCT), Real-Time Position Management (RPM™) and body
      immobilization system (see figure 1). Specifically, the effect of image-guided SBRT treatment
      on clinical tumor response rate, local control and progression-free survival will be studied.
      This study will examine target volumes and relevant margins determined by an assessment using
      4D PET and repeated 4D CT. These data will allow us to evaluate and determine the impact of
      the body immobilization system on the planning target volume (PTV) margins, patient's
      breathing pattern, target motion, and inter-treatment targets shifts.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC</measure>
    <time_frame>2 years</time_frame>
    <description>The Number of Patients that completed SBRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with Progression Free Survival at 2 Years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of Imaging Response With Serum Protein and Peptide Profiles</measure>
    <time_frame>2 years</time_frame>
    <description>Research blood draws looking at imaging repsonse before and after radiation in relationship to serum protein and peptide profiles</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>4D CT</condition>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>SRS</other_name>
    <other_name>Trilogy</other_name>
    <other_name>True Beam</other_name>
    <other_name>Cyber Knife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The patient must be over the age of 18 years. Histologic confirmation of primary NSCLC of
        the lung tumor must be complete prior to SBRT treatment.

        The following stages of NSCLC patients would be eligible for the study:

        Stage I:

        T1 N0 M0 T2 N0 M0 (Size ≤ 5 cm)

        Stage II:

        T3 N0 M0 (Chest wall invasion only, Size ≤ 5 cm)

        Staging Tumor size and characteristics: they will be determined by PET-CT scan

        Nodal disease:

        Patients with chest CT scan demonstrating hilar or mediastinal nodes &lt;1cm and/or PET
        negative would be considered N0 disease.

        Patients who have hilar or mediastinal nodes &gt; 1 cm and PET scan negative may be considered
        N0 disease.

        If PET scan demonstrates suspicious uptake or abnormal uptake, these patients would be
        eligible, if a directed biopsy (by mediastinoscopy, Chamberlein procedure or other
        modalities such as trans-bronchial biopsy, CT guided biopsy) is negative.

        Metastases:

        Evaluated by PET-CT scanning and biopsy as indicated

        The patient must have an ECOG/Zubrod performance status of 0, 1, or 2. In order to be
        considered medically-inoperable, the patient must meet at least one major criterion or meet
        a minimum of 2 minor criteria as described below.

        MAJOR CRITERIA:

        FEV1 &lt; 50% or predicted postoperative FEV1 &lt; 40% DLCO &lt; 50% or predicted postoperative DLCO
        &lt; 40% Exercise induced maximal exercise oxygen consumption (MVO2)&lt;15 ml/kg/min Thoracic
        surgery consultation should be obtained from a Board Certified Thoracic surgeon who in
        collaboration with a radiation oncologist should determine if the patient is medically
        operable This criterion would be mandatory

        MINOR CRITERIA:

        Age &gt; 80 Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater
        than 40mm Hg) Oxygen requirement (using the Medicare criteria for home oxygen requirements
        [i.e., room air oxygen saturation of 88% or less]) Congestive heart failure (any three of
        the following must be documented: dyspnea, peripheral edema, chest x-ray with interstitial
        edema or cardiomegaly, rales, or congestion) Poor left ventricular function (defined as an
        ejection fraction of 40% or less) Severe cerebral (with CVA or recent TIA) or severe
        peripheral vascular disease Diabetes Mellitus with severe organ damage such as End-Stage
        Renal Disease (ESRD), Blindness, Vascular disease.

        CBC, Diff and platelets, Comprehensive metabolic panel within 28 days of registration
        meeting the following criteria

        leukocytes &gt;3,000/mcL absolute neutrophil count &gt;1,500/mcL hemoglobin &gt;9 g/dL (hemoglobin
        may be supported by transfusion or erythropoietin or other approved hematopoietic growth
        factors) platelets &gt;100,000/mcL total bilirubin &lt;1.5x institutional upper limit of normal
        creatinine within normal institutional limits OR creatinine clearance &gt;60 mL/min/1.73 m2
        for patients with creatinine levels above institutional normal.

        Females of child-bearing age must be using a reliable form of birth control. The patient
        must provide a signed and dated written informed consent PRIOR to registration and prior to
        undergoing any study-related procedures.

        The patient must provide written authorization to allow for the use and disclosure of their
        protected Health information.

        Conditions for Patient Ineligibility The patient's weight exceeds the tolerances of the
        institution's imaging and treatment platform/couch.

        The patient has received thoracic radiation therapy in the same region as the current SBRT
        planned treatment area. The patient has completed chemotherapy within 30 days of treatment.
        T2: Tumor size &gt; 5 cm, T3 tumors (except T3 by virtue of chest wall invasion and ≤ 5cm), T4
        tumors. Presence of N1, N2 or N3 disease per previously described criteria would also be
        excluded.

        Pancoast tumors would be excluded. Current distant metastatic disease (M1) (preferably
        biopsy proven). The patient is a female with child-bearing potential who refuses to obtain
        a serum pregnancy test prior to the initiation of treatment.

        The patient is pregnant or a female who is nursing an infant. The patient is planning on
        undergoing systemic therapy within 2 weeks after the last fraction of radiation The patient
        has an active systemic or pulmonary infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight E Heron, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Shadyside Radiation Oncology Department</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <results_first_submitted>December 4, 2017</results_first_submitted>
  <results_first_submitted_qc>June 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2018</results_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Steven Burton</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stereotactic Radiosurgery</title>
          <description>3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent
Stereotactic Radiosurgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stereotactic Radiosurgery</title>
          <description>3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent
Stereotactic Radiosurgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC</title>
        <description>The Number of Patients that completed SBRT</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery</title>
            <description>3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent
Stereotactic Radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC</title>
          <description>The Number of Patients that completed SBRT</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Progression-free Survival</title>
        <description>Number of patients with Progression Free Survival at 2 Years</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery</title>
            <description>3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent
Stereotactic Radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Progression-free Survival</title>
          <description>Number of patients with Progression Free Survival at 2 Years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of Imaging Response With Serum Protein and Peptide Profiles</title>
        <description>Research blood draws looking at imaging repsonse before and after radiation in relationship to serum protein and peptide profiles</description>
        <time_frame>2 years</time_frame>
        <population>Blood draw samples were not drawn nor analyzed for this study</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery</title>
            <description>3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent
Stereotactic Radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Imaging Response With Serum Protein and Peptide Profiles</title>
          <description>Research blood draws looking at imaging repsonse before and after radiation in relationship to serum protein and peptide profiles</description>
          <population>Blood draw samples were not drawn nor analyzed for this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stereotactic Radiosurgery</title>
          <description>3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent
Stereotactic Radiosurgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Holeva</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-623-1275</phone>
      <email>holevakd@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

